Oxford Genome Sciences to collaborate with Amgen on antibodies

Oxford Genome Sciences (UK) Ltd has entered into a strategic collaboration with Amgen Inc to discover, develop and commercialise therapeutic antibodies for the treatment of cancer. Financial terms were not disclosed.